Clinical Evidence Hub

Built for the patients you see every day.

Peer-reviewed and practice data supporting KSPtabs for calcium stone formers, hypocitraturia, and recurrent stone prevention.

2026 AUA Guideline

Methods + Limitations Visible

Request Clinical Samples → Explore the Evidence →

Urologist reviewing KSPtabs clinical research and citrate study data

+33% Urinary Citrate
Peer-reviewed crossover study

+128% Citrate in Practice Data
35-patient pre/post evaluation

15 mEq Alkalinizing Agents
Per tablet, as labeled

2026 AUA Guideline
Medical management of kidney stones

Crossover Study · Evidence Library · AUA Guideline · Clinical Application Request Samples →

KSPtabs raises urinary citrate by 33% and improves urine pH in a prospective crossover trial.

597 → 797

mg/day Urinary Citrate

p=0.037

6.46 → 6.86

Urine pH

change +0.40 · p=0.037

n=10

Healthy Adult Volunteers

Prospective Crossover Design

+33%

Median Urinary Citrate

The published crossover trial measuring KSPtabs' direct effect on urinary citrate and pH. Participants completed 24-hour urine collections at baseline and again while taking KSPtabs, each serving as their own control, showing statistically significant improvements on both endpoints.

Canvasser NE, Rivera M, Bechis SK, et al. Urology. 2022;168:72–78. First presented as an AUA 2021 meeting abstract.

Prospective Crossover 24-Hr Urine KSP-Specific

Urology · 2022

Over-the-counter alkali agents to raise urine pH and citrate excretion: a prospective crossover study in healthy adults.

Ten healthy adult volunteers completed a baseline 24-hour urine collection, then repeated it while taking KSPtabs, each participant serving as their own control. Median urinary citrate increased from 597 to 797 mg/day (+33%) and urine pH from 6.46 to 6.86 (+0.40), both p=0.037. The study also included a second over-the-counter alkali supplement as a comparator arm. Limitations: small healthy-volunteer sample, not stone formers; no stone recurrence endpoint was evaluated.

Read the Study → Earlier AUA 2021 meeting abstract →

The Evidence Supporting evidence sources

Methods and limitations visible for each entry.

Confirms citrate content

Published · Urology 2021

Complementary and alternative medicine use in first-time and recurrent kidney stone formers.

Joshi A, Tallman JE, Calvert JK, et al. Urology (Gold Journal), 2021;156:58–64. Alkali content measured per serving.

19.8 mEq Key Lime 20.2 mEq Very Berry

Read Study →

Real-world patient outcomes

Practice Data · On File

Effect of KSPtabs supplementation on 24-hour urine parameters.

35-patient pre/post evaluation. Data on file.

+128% Citrate +50% Vol. n=35

Read Study →

Recent research · Hydration is hard to sustain

External Evidence · Lancet 2026

Why daily adherence matters

The PUSH trial (1,658 stone formers) found that an intensive program to increase fluid intake modestly raised urine volume but did not significantly reduce symptomatic stone recurrence over two years. The results show how hard it is for patients to sustain high fluid intake. KSPtabs is designed to make daily hydration easier by pairing it with citrate and alkali in a drink patients enjoy. This trial did not test KSPtabs or citrate supplementation.

1,658 Participants

RCT Hydration Behavior

Read Study →

Studies vary in design, sample size, and clinical endpoint. Limitations are noted for each entry. This page is not a substitute for full-text review.

Practical Considerations

Citrate support only works when patients can stay with it.

Prescription potassium citrate can be effective, but cost, pill size and adherence can be barriers. KSPtabs provides citrate-containing alkalinizing agents in an effervescent format designed to become part of the patient's daily hydration.

Factor Rx Potassium Citrate KSPtabs

Alkalinizing agents Prescribed dosing varies 15 mEq / tablet

Format Tablets / Capsules Effervescent drink

Hydration built in No Yes

Prescription Required OTC

Patient cost* Varies by dose / coverage as little as $1.35/day

*KSPtabs cost based on 2 tablets daily with the 24 tube subscription. Rx cost varies by dose and coverage.

2026 AUA Guideline

Cited in the 2026 AUA Guideline

The 2026 AUA Medical Management of Kidney Stones guideline is published in two parts. Part II, covering treatment and follow up, addresses alkali citrate therapy and references the published KSPtabs crossover study (Canvasser et al., Urology, 2022).

KSPtabs delivers 15 mEq of total alkalinizing agents per tablet, including 5 mEq of potassium citrate, in an effervescent format patients can use daily, at as little as $1.35 a day.

Part I: Evaluation and Dietary Management →
Part II: Treatment and Follow Up →

Clinical Application

Does your patient
fit the profile?

KSPtabs was built for specific patient presentations. See the full clinical guide — including patient selection criteria, 24-hour urine targets, and prescribing considerations.

See Which Patients Benefit → Patient selection criteria, prescribing notes & sample request

Hypocitraturia

Low urinary citrate documented on 24-hour collection — the core indication KSPtabs was developed to address.

Recurrent calcium stone formers

Patients seeking additional citrate support between or after stone events.

Low urine pH / uric acid risk

Patients where urinary alkalinization is part of the management strategy.

Interested in evaluating KSPtabs with your patients?

Free trial pack of all 3 flavors

Request Clinical Samples →

Dietary supplement. Not intended to diagnose, treat, cure, or prevent disease. For healthcare professional use only.

KSPtabs | Clinical Evidence Hub

Your cart is empty

Home page

Home page

Your cart

Estimated total

Built for the patients you see every day.

Over-the-counter alkali agents to raise urine pH and citrate excretion: a prospective crossover study in healthy adults.

Complementary and alternative medicine use in first-time and recurrent kidney stone formers.

Effect of KSPtabs supplementation on 24-hour urine parameters.

Why daily adherence matters

Citrate support only works when patients can stay with it.

Cited in the 2026 AUA Guideline

Interested in evaluating KSPtabs with your patients?